Alivus Life Sciences Limited has announced the incorporation of its wholly-owned subsidiary, “Alivus Life Sciences Do Brasil Ltda.”, in the state of Sao Paulo, Brazil. This strategic move, effective September 15, 2026, involves an initial subscription to the subsidiary’s share capital amounting to R$ 500,000.00. The establishment in Brazil signifies the company’s international expansion efforts within the pharmaceuticals sector.
International Expansion Initiative
Alivus Life Sciences Limited, formerly Glenmark Life Sciences Limited, has officially established a new wholly-owned subsidiary in Brazil. The entity, named Alivus Life Sciences Do Brasil Ltda., was incorporated in the state of Sao Paulo on September 15, 2026. This strategic development is part of the company’s broader international growth strategy within the global pharmaceutical market.
Subsidiary Details and Investment
The newly formed Brazilian subsidiary has an authorized capital of R$ 500,000.00, divided into 500,000 shares. Alivus Life Sciences Limited will subscribe to the entire paid-up share capital, amounting to R$ 500,000.00 (five hundred thousand reais), representing 100% ownership. This investment is crucial for setting up operations and future business development in the Brazilian market. The company has also secured necessary approvals from the Federative Republic of Brazil’s National Registrar of Legal Entities for this incorporation.
Strategic Rationale
The incorporation of Alivus Life Sciences Do Brasil Ltda. allows Alivus Life Sciences Limited to directly engage in the Brazilian pharmaceutical landscape. While the subsidiary is in its nascent stages and does not yet have a turnover, this move is expected to pave the way for future product launches and market penetration in a key South American region. The promoter and promoter group of Alivus Life Sciences Limited do not hold any interest in this Brazilian entity, ensuring the transaction is conducted at arms-length.
Source: BSE
